Search Results - "amyloid"
Suggested Topics within your search.
Suggested Topics within your search.
- Amyloid 74
- Alzheimer Disease 53
- Prions 48
- Alzheimer's disease 39
- metabolism 21
- Neurodegenerative Diseases 20
- Protein Folding 18
- pathology 18
- physiopathology 18
- Nervous system 17
- Degeneration 16
- Proteins 16
- Protein Conformation 15
- drug therapy 15
- Genetic aspects 14
- genetics 14
- Amyloid beta-Peptides 13
- Chemotherapy 13
- Treatment 12
- therapy 11
- Amyloid beta-protein 9
- Pathophysiology 9
- Protein folding 9
- Brain 8
- Dementia 8
- Diagnosis 8
- Pathology 8
- Frontotemporal Dementia 7
- Amyloidosis 6
- Diagnostic Imaging 6
-
61
Ischemic blood-brain barrier and Alzheimer's amyloid plaques development
Published 2008Table of Contents: “…Contents: Ischemic blood-brain barrier involved in Alzheimer's amyloid plaques development and full-blown Alzheimer's disease -- Brain ischemia starts Alzheimer's disease -- Association and risk factors for Alzheimer's disease -- Ischemic mechanisms in Alzheimer's disease in general.…”
Get full text
Series
Electronic Video -
62
Ischemic blood-brain barrier and Alzheimer's amyloid plaques development
Published 2008Table of Contents: “…Contents: Ischemic blood-brain barrier involved in Alzheimer's amyloid plaques development and full-blown Alzheimer's disease -- Brain ischemia starts Alzheimer's disease -- Association and risk factors for Alzheimer's disease -- Ischemic mechanisms in Alzheimer's disease in general.…”
Get full text
Series
Electronic Video -
63
Adapting proteostasis to ameliorate aggregation-associated amyloid diseases
Published 2018Table of Contents: “…Contents: Protein folding, misfolding, aggregation -- The proteostasis network and its regulation -- Gain and loss of function diseases -- The transthyretin (TTR) amyloidosis -- Kinetic stabilizers & clinical trial results -- Tafamidis & Diflunisal: evidence for the amyloid hypothesis -- Improving protein misfolding/aggregation diseases -- The unfolded protein response (UPR) and its arm-selective activators -- ATF6 activation & reduction of TTR mutant -- Clinical trials in amyloidosis with cardiac involvement.…”
Get full text
Series
Electronic Video -
64
Abeta toxicity Part 2 /
Published 2011Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
65
Molecular biology of Alzheimer's disease genes and mechanisms involved in amyloid generation /
Published 1998Subjects: An electronic book accessible through the World Wide Web; click to view
Electronic eBook -
66
Abeta toxicity Part 1 /
Published 2011Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
67
A molecular understanding of Alzheimer's disease
Published 2007Table of Contents: “…Contents: Usefulness of genetics in understanding AD -- Pathology of diseases -- Amyloid protein -- Genetic maps -- Mechanism of late onset Alzheimer's -- Role of presenilin in amyloid pathology -- Tau and frontotemporal dementia -- Tau splice site mutations -- Pathways to neurodegeneration.…”
Get full text
Series
Electronic Video -
68
Abeta toxicity 2
Published 2011Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
69
Abeta toxicity 2
Published 2011Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
70
BACE lead target for orchestrated therapy of Alzheimer's disease /
Published 2010Subjects: An electronic book accessible through the World Wide Web; click to view
Electronic eBook -
71
Current directions in the prevention and treatment of Alzheimer's disease
Published 2018Table of Contents: “…Contents: Amyloid build-up and the importance of early diagnosis -- The potential of inhibiting vs. clearing amyloid aggregation -- Different potential therapeutic approaches designed for different stages of Alzheimer's -- The future of therapies targeting amyloid deposition.…”
Get full text
Electronic Audio -
72
Abeta toxicity 1
Published 2011Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
73
Abeta toxicity 1
Published 2011Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
74
Oxidative modification of brain proteins in Alzheimer's disease and models thereof role of amyloid beta-peptide (1-42) and insights from redox proteomics /
Published 2007Table of Contents: “…Contents: Alzheimer's disease and mild cognitive impairment -- Oxidative stress markers in brain, including markers for protein oxidation and lipid peroxidation -- Amyloid beta-peptide-mediated oxidative stress and Alzheimer's disease -- Redox proteomics identification of oxidatively modified brain proteins, leading to new insights into protein dysfunction in and neurotoxicity of brain cells in Alzheimer's disease and mild cognitive impairment.…”
Get full text
Series
Electronic Video -
75
Oxidative modification of brain proteins in Alzheimer's disease and models thereof role of amyloid beta-peptide (1-42) and insights from redox proteomics /
Published 2007Table of Contents: “…Contents: Alzheimer's disease and mild cognitive impairment -- Oxidative stress markers in brain, including markers for protein oxidation and lipid peroxidation -- Amyloid beta-peptide-mediated oxidative stress and Alzheimer's disease -- Redox proteomics identification of oxidatively modified brain proteins, leading to new insights into protein dysfunction in and neurotoxicity of brain cells in Alzheimer's disease and mild cognitive impairment.…”
Get full text
Series
Electronic Video -
76
Oxidative modification of brain proteins in Alzheimer's disease and models thereof role of amyloid beta-peptide (1-42) and insights from redox proteomics /
Published 2007Table of Contents: “…Contents: Alzheimer's disease and mild cognitive impairment -- Oxidative stress markers in brain, including markers for protein oxidation and lipid peroxidation -- Amyloid beta-peptide-mediated oxidative stress and Alzheimer's disease -- Redox proteomics identification of oxidatively modified brain proteins, leading to new insights into protein dysfunction in and neurotoxicity of brain cells in Alzheimer's disease and mild cognitive impairment.…”
Get full text
Series
Electronic Video -
77
Current directions in the prevention and treatment of Alzheimer's disease
Published 2018Table of Contents: “…Contents: Amyloid build-up and the importance of early diagnosis -- The potential of inhibiting vs. clearing amyloid aggregation -- Different potential therapeutic approaches designed for different stages of Alzheimer's -- The future of therapies targeting amyloid deposition.…”
Get full text
Series
Electronic Audio -
78
Current directions in the prevention and treatment of Alzheimer's disease
Published 2018Table of Contents: “…Contents: Amyloid build-up and the importance of early diagnosis -- The potential of inhibiting vs. clearing amyloid aggregation -- Different potential therapeutic approaches designed for different stages of Alzheimer's -- The future of therapies targeting amyloid deposition.…”
Get full text
Series
Electronic Audio -
79
Targeting Aß oligomers a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease /
Published 2014Table of Contents: “…Contents: The oligomer cascade hypothesis for Alzheimer's Disease -- Why the oligomer hypothesis has largely supplanted the amyloid cascade hypothesis -- The role of AβOs in memory failure and the major facets of AD neuropathology -- Mechanisms by which AβOs instigate neurotoxicity -- Why AβOs accumulate in the first place -- How AβOs offer superb targets for novel AD diagnostics and disease-modifying therapeutics -- Beside its direct link to Alzheimer's disease, the discovery of toxic Aβ oligomers has provided a novel structural archetype for toxins germane to more than two dozen diseases of protein mis-folding, including Diabetes, Parkinson's, and prion diseases.…”
Get full text
Series
Electronic Video -
80
Targeting Aß oligomers a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease /
Published 2014Table of Contents: “…Contents: The oligomer cascade hypothesis for Alzheimer's Disease -- Why the oligomer hypothesis has largely supplanted the amyloid cascade hypothesis -- The role of AβOs in memory failure and the major facets of AD neuropathology -- Mechanisms by which AβOs instigate neurotoxicity -- Why AβOs accumulate in the first place -- How AβOs offer superb targets for novel AD diagnostics and disease-modifying therapeutics -- Beside its direct link to Alzheimer's disease, the discovery of toxic Aβ oligomers has provided a novel structural archetype for toxins germane to more than two dozen diseases of protein mis-folding, including Diabetes, Parkinson's, and prion diseases.…”
Get full text
Series
Electronic Video